New Delhi: Torrent Pharmaceuticals Limited has informed that the United States Food and Drug Administration (USFDA) has completed an inspection of the company’s manufacturing facility located at Dahej, Gujarat, with zero observations, indicating full compliance with regulatory requirements.In an intimation to the exchanges, Torrent Pharmaceuticals stated that the USFDA conducted the inspection at its Dahej manufacturing unit over a five-day period, from January 19, 2026 to January 23, 2026. The company confirmed that the inspection has been formally concluded without any regulatory observations being issued.The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Torrent Pharmaceuticals clarified that the inspection concluded with zero observations, meaning no Form 483 or other adverse remarks were issued by the USFDA at the end of the audit.Also Read: Torrent Pharma to Raise Up to Rs 12,500 Cr via Bonds for JB Chemicals DealAccording to Torrent Pharmaceuticals Limited, the successful conclusion of the USFDA inspection with zero observations reflects the robustness of its quality systems and adherence to global current good manufacturing practice (cGMP) standards.Also Read: Torrent Pharma Gets CDSCO Panel Nod to Manufacture, Market Prucalopride Oral Solution